التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
Amgen Inc
Closed
Sector Healthcare
294.53 1.6
Overview
Share price change
24h
Min
293.51
Max
295.12
Income | 2.1B 2.8B |
|---|---|
Sales | 110M 8.5B |
P/E Sector Avg | 44.64 94.998 |
EPS | 5.58 |
Dividend yield | 2.793 |
Profit margin | 33.294 |
Employees | 26,700 |
EBITDA | 441M 3.4B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +16.27 upside |
Dividend yield Sector Avg | 2.79% 2.40% |
|---|---|
Next Earnings | ٤ فبراير ٢٠٢٥ |
Next Dividend date | ٩ ديسمبر ٢٠٢٤ |
Next Ex Dividend date | ١٣ فبراير ٢٠٢٥ |
Market Cap | -18B 154B |
|---|---|
Previous open | 292.93 |
Previous close | 294.53 |
News Sentiment
By Acuity
30%
70%
73 / 392 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Neutral Evidence
Amgen Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Amgen Inc Forecast
Price Target
By TipRanks
16.27% upside
12 Months Forecast
Average 342.44 USD 16.27%
High 405 USD
Low 215 USD
Based on 23 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.
Sentiment
By Acuity
73 / 392 Ranking in Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Amgen Inc
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
